Dermatology - University Hospitals Birmingham NHS Foundation Trust, University Hospital Birmingham, Birmingham, B15 2TH, UK.
Future Oncol. 2017 Nov;13(27):2405-2411. doi: 10.2217/fon-2017-0263. Epub 2017 Aug 14.
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Response rates >75% with manageable adverse effects in refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma led to accelerated approval for both. Phase II studies in CD30-expressing CTCL followed and showed similar efficacy, which was ratified in a Phase III trial of BV versus physician's choice (methotrexate or bexarotene) showing significant improved responses without increase in severe adverse effects although peripheral neuropathy is frequent. BV provides an effective targeted therapy for CD30-expressing cutaneous lymphomas and welcome addition to our anti-CTCL armory.
CD30 阳性原发性皮肤 T 细胞淋巴瘤（CTCL）包括蕈样真菌病、间变大细胞淋巴瘤和淋巴母细胞性丘疹病 A 型。 Brentuximab vedotin（BV）由一种针对 CD30 的抗体与蛋白酶可裂解接头组成，与 vedotin 相连。CD30 结合允许 BV 内化，诱导细胞周期停滞和细胞凋亡。在难治性霍奇金淋巴瘤和系统性间变大细胞淋巴瘤中，超过 75%的反应率和可管理的不良反应导致了这两种药物的加速批准。随后进行了 CD30 表达 CTCL 的 II 期研究，显示出相似的疗效，在 BV 与医生选择（甲氨蝶呤或贝沙罗汀）的 III 期试验中得到了证实，无严重不良反应增加的情况下，显著提高了反应率，尽管周围神经病变很常见。BV 为表达 CD30 的皮肤淋巴瘤提供了一种有效的靶向治疗方法，是我们对抗 CTCL 武器库的可喜补充。
